Inspiration Research Limited

Toronto, Ontario M5T 3A9

2 studies enrolling now · 16 studies all time

What they study most

Alpha 1-Antitrypsin Deficiency, Alpha1-Antitrypsin Deficiency, Alpha1-antitrypsin Deficiency, Asthma, COVID-19, Chronic Obstructive Pulmonary Disease, Emphysema, HBeAg-negative Chronic Hepatitis B, HBeAg-positive Chronic Hepatitis B, Hepatitis C, Chronic, Pulmonary Disease, Chronic Obstructive, Refractory or Unexplained Chronic Cough

Studies at this site

• Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein — Recruiting now
• Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis) — Recruiting now
• Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough — Running, not enrolling
• Registry of Asthma Patients Initiating DUPIXENT® — Completed
• Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma — Running, not enrolling
• Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Positive for Hepatitis B e Antigen — Completed
• Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Negative for Hepatitis B e Antigen — Completed
• Dapsone Coronavirus SARS-CoV-2 Trial (DAP-CORONA) COVID-19 — Status unconfirmed
• GB001 in Adult Subjects With Moderate to Severe Asthma — Completed
• Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency — Stopped early
• Efficacy/Safety of HA Inhalation Solution for Hereditary Emphysema in Patients With Alpha-1 Antitrypsin Deficiency — Completed
• Longitudinal Cohort Study in Participants With Severe Asthma to Assess Biomarkers — Completed
• A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response — Completed
• Simvastatin Therapy for Moderate and Severe COPD — Stopped early
• A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD) — Completed
• A Study of Lebrikizumab (RO5490255) in Participants With Severe Oral Corticosteroids (OCS) Dependent Asthma — Completed